Johnson & Johnson President Brings Extensive McNeil Background To Post
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson's appointment of James Lenehan, 53, as president signals a strong commitment by the company to its consumer products segments, despite the firm's shift in emphasis toward its pharmaceutical business over the past ten years
You may also be interested in...
J&J asks MHRA for antifungal switch
Johnson & Johnson's McNeil division requests the U.K. Medicines and Healthcare products Regulatory Agency switch its antifungal Daktarin Intensiv Cream (ketoconazole 2%) from pharmacy to general sale list status. The same active ingredient is found in J&J's Nizoral Anti-dandruff Shampoo which has been GSL in the U.K. since 2001 and switched to U.S. OTC sale in 1997 (1"The Tan Sheet" Jan. 28, 2002)
J&J asks MHRA for antifungal switch
Johnson & Johnson's McNeil division requests the U.K. Medicines and Healthcare products Regulatory Agency switch its antifungal Daktarin Intensiv Cream (ketoconazole 2%) from pharmacy to general sale list status. The same active ingredient is found in J&J's Nizoral Anti-dandruff Shampoo which has been GSL in the U.K. since 2001 and switched to U.S. OTC sale in 1997 (1"The Tan Sheet" Jan. 28, 2002)
J&J asks MHRA for antifungal switch
Johnson & Johnson's McNeil division requests the U.K. Medicines and Healthcare products Regulatory Agency switch its antifungal Daktarin Intensiv Cream (ketoconazole 2%) from pharmacy to general sale list status. The same active ingredient is found in J&J's Nizoral Anti-dandruff Shampoo which has been GSL in the U.K. since 2001 and switched to U.S. OTC sale in 1997 (1"The Tan Sheet" Jan. 28, 2002)